Half-life of tolbutamide in patients with chronic respiratory failure

Chronic pulmonary disease and antipyrine disposition.

“…This finding, however, is in contrast to those of Ambre and his colleagues (Ambre, Graeff, Bures, Haupt & Deason, 1977) who observed that although antipyrine clearances were significantly higher in patients with bronchogenic carcinoma compared to normal controls, clearances in patients with chronic lung disease alone were no different. On the other hand, data suggesting that oxidative metabolism of tolbutamide and ethanol might be enhanced in patients with chronic respiratory disease Sotaniemi, Arvela, Huhti & Koivisto, 1971;Sotaniemi, Isoaho, Huhti, Huikko & Koivisto, 1972) support our own.…”

Clinical Pharmacokinetics of Sulphonylurea Hypoglycaemic Drugs

“…Tolbutamide: Stowers et al (195S): 3000mg po; Knauff et al (1959b): 1500-2000mg iv/po; West and Johnson (1959): 500-1000mg po; Nelson et al (1962): 500mg po; Christensen et al (1963Christensen et al ( ): 1000Ueda et al (1963): 1000-1500mg iv; Dubach et al (1966): 1000mg iv; Brook et al (1968): 1000mg iv; Christensen and Skorsted (1969): 750mg iv; Kristensen and Christensen (1969): iv and po; Schultz and Schmidt (1970): 1000mg iv; Sotaniemi et al (1971): 1000mg iv; Andreasen and Vesell (1974): 1000mg iv and po; : 1000mg iv; Lumholtz et al (1975): 750mg iv; Scott and Poffenbarger (1979); -500mg iv.…”

Reaction routes for the formation of a Cu2ZnSnS4 absorber material from homogenous ethanol-based solution

“…13,14 Hydrazine should therefore be used only with adequate protective measures in place to avoid contact with either the vapor or liquid and/or ignition sources. 15,16 To address the hydrazine issue, different types of precursor solution were introduced by selecting suitable solvents. The requirements for selecting a solvent should…”